Skip to main content

Table 6 Differences between treatment arms in voice, quality of life and QALYs at 3, 6, and 12 months, after adjusting for baseline values

From: Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: preliminary cost-consequence analysis of the PD COMM pilot randomised controlled trial

Outcome

LSVT® LOUDa vs NHS SLT estimate (95% CI)

NHS SLTa vs control estimate (95% CI)

LSVT® LOUDa vs control estimate (95% CI)

VHI

 3 months

 6 months

 12 months

2.0 (− 7.0, 10.9)

8.4 (− 0.6, 17.4)

6.7 (− 3.7, 17.1)

6.7 (− 1.0, 14.4)

3.6 (− 3.6, 10.7)

0.03 (− 9.2, 9.3)

8.3 (− 0.9, 17.6)

12.1 (3.5, 20.8)

6.3 (v3.1, 15.6)

PDQ39-COMM

 3 months

 6 months

 12 months

3.6 (− 5.9, 13.2)

 − 0.06 (− 0.15, 0.04)

1.3 (− 10.4, 13.0)

4.5 (− 4.1, 13.7)

0.9 (− 8.2, 9.9)

1.4 (− 8.3, 11.1)

8.7 (− 1.1, 18.5)

6.6 (− 2.4, 15.6)

2.5 (− 9.2, 14.2)

PDQ-39 Summary

 3 months

 6 months

 12 months

1.4 (− 4.0, 6.7)

3.9 (− 2.2, 10.1)

1.1 (− 5.3, 7.0)

3.3 (− 1.0, 7.7)

 − 0.2 (− 5.1, 4.7)

 − 3.1 (− 7.6, 1.5)

5.2 (− 0.1, 10.4)

4.4 (− 0.7, 9.4)

 − 2.3 (− 8.8, 4.2)

EQ-5D-3L

 3 months

 6 months

 12 months

0.07 (− 0.03, 0.16)

0.05 (− 0.08, 0.17)

0.01 (− 0.14, 0.17)

 − 0.15 (− 0.36, − 0.26)

 − 0.04 (− 0.15, 0.06)

 − 0.04 (− 0.17, 0.94)

 − 0.09 (− 0.21, 0.04)

 − 0.00 (− 0.12, 0.12)

 − 0.02 (− 0.17, 0.14)

ICECAP-O

 3 months

 6 months

 12 months

 − 0.01 (− 0.8, 0.06)

 − 0.05 (− 0.16, 0.05)

 − 0.06 (− 0.15, 0.04)

0.02 (− 0.05, 0.09)

0.08 (− 0.02, 0.17)

0.08 (− 0.01, 0.17)

0.01 (− 0.07, 0.09)

0.02 (− 0.11, 0.07)

0.01 (− 0.07, 0.09)

Total QALYs

0.03 (− 0.05, 0.10)

 − 0.06 (− 0.15, 0.02)

 − 0.04 (− 0.12, 0.05)

  1. VHI ranges from 0 to 120; PDQ-39 summary index and communication domain score range from 0 to 100, where low score is good. Positive difference favours treatment
  2. EQ-5D-3L ranges from − 0.59 to 1; ICECAP-O from 0 to 1, where high score is good. Negative difference favours treatment
  3. a reference arm